Munich Reinsurance Co Stock Corp in Munich Grows Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Munich Re dramatically increased its stake in Zimmer Biomet by 4,766.7% in Q4, adding 53,053 shares to hold 54,166 shares worth $4.92M, while other institutions (notably M&T Bank) also made large buys and total institutional ownership stands at 88.89%.
• Zimmer Biomet beat Q results with EPS $2.42 vs $2.38 and revenue $2.24B (up 10.9% YoY), issued FY2026 guidance of 8.300–8.450 EPS (consensus ~8.39) and declared a quarterly dividend of $0.24 (annualized $0.96, 1.1% yield).

Munich Reinsurance Co Stock Corp in Munich increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 4,766.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,166 shares of the medical equipment provider's stock after acquiring an additional 53,053 shares during the period. Munich Reinsurance Co Stock Corp in Munich's holdings in Zimmer Biomet were worth $4,918,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ZBH. M&T Bank Corp raised its stake in shares of Zimmer Biomet by 15,705.6% in the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider's stock valued at $321,158,000 after acquiring an additional 3,548,998 shares in the last quarter. Dodge & Cox raised its stake in shares of Zimmer Biomet by 5.1% in the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider's stock valued at $2,286,793,000 after acquiring an additional 1,118,710 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Zimmer Biomet by 276.6% in the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider's stock valued at $118,627,000 after acquiring an additional 955,284 shares in the last quarter. Capital International Investors raised its stake in shares of Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider's stock valued at $743,749,000 after acquiring an additional 778,467 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its stake in shares of Zimmer Biomet by 3,633.7% in the third quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider's stock valued at $45,729,000 after acquiring an additional 451,816 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Down 1.3%

ZBH opened at $91.27 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $108.29. The business's 50-day simple moving average is $93.59 and its 200-day simple moving average is $93.09. The stock has a market capitalization of $17.67 billion, a P/E ratio of 25.78, a price-to-earnings-growth ratio of 1.89 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same quarter last year, the company posted $2.31 earnings per share. The business's revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.39 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet's dividend payout ratio (DPR) is currently 27.12%.

Insider Activity

In related news, SVP Lori Winkler sold 2,650 shares of the firm's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company's stock, valued at $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.28% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ZBH shares. Citigroup reiterated a "buy" rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Barclays cut their price target on Zimmer Biomet from $104.00 to $100.00 and set an "underweight" rating on the stock in a research note on Thursday, February 12th. Wall Street Zen cut Zimmer Biomet from a "buy" rating to a "hold" rating in a research note on Sunday, April 19th. Wells Fargo & Company raised their price target on Zimmer Biomet from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 11th. Finally, Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $105.95.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.